Scholar Rock Presents New Data From Phase 1 DRAGON Trial Showing Anti-Tumor Activity In Anti-PD-1 Resistant Metastatic CcRCC Patients And Supporting SRK-181 Continued Tolerability
Portfolio Pulse from Benzinga Newsdesk
Scholar Rock has presented new data from its Phase 1 DRAGON trial, showing anti-tumor activity in anti-PD-1 resistant metastatic ccRCC patients. The data supports the continued tolerability of SRK-181 and shows a disease control rate of 57% and an objective response rate of 21.4%. The company will discuss the SRK-181 program during a conference call on its Q3 2023 financial results and business updates.
November 03, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scholar Rock's new data from the Phase 1 DRAGON trial supports the continued use of SRK-181 in treating ccRCC patients. This could potentially boost the company's reputation and stock value.
The positive results from the Phase 1 DRAGON trial could potentially increase investor confidence in Scholar Rock, leading to a rise in the company's stock value. The continued success of SRK-181 also indicates a strong product pipeline, which is a positive sign for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100